The American Journal of Managed Care1h
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...
Medical Dialogues3h
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
PharmExec9h
FDA Approves Novartis’ Vanrafia for Primary Immunoglobulin A Nephropathy
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
PMLive7h
Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Knowridge Science Report9h
Rare infection linked to common diabetes drug: what patients should know
The study found that some people taking SGLT2 inhibitors developed a dangerous infection called Fournier gangrene. This ...